Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Goodwill (2017 - 2025)

Ultragenyx Pharmaceutical has reported Goodwill over the past 9 years, most recently at $44.0 million for Q4 2025.

  • Quarterly Goodwill changed 0.0% to $44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $44.0 million for FY2025, 0.0% changed from the prior year.
  • Goodwill was $44.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $44.4 million in the prior quarter.
  • Over five years, Goodwill peaked at $44.4 million in Q1 2021 and troughed at $44.0 million in Q4 2024.
  • The 5-year median for Goodwill is $44.4 million (2021), against an average of $44.4 million.
  • Year-over-year, Goodwill changed 0.0% in 2021 and then decreased 0.91% in 2024.
  • A 5-year view of Goodwill shows it stood at $44.4 million in 2021, then changed by 0.0% to $44.4 million in 2022, then changed by 0.0% to $44.4 million in 2023, then decreased by 0.91% to $44.0 million in 2024, then changed by 0.0% to $44.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Goodwill are $44.0 million (Q4 2025), $44.4 million (Q3 2025), and $44.4 million (Q2 2025).